Start Date
April 15, 2021
Primary Completion Date
December 17, 2023
Study Completion Date
May 13, 2026
nivolumab
Specified dose on Specified days
ipilimumab
Specified dose on Specified days
cabozantinib
Specified dose on Specified days
docetaxel
Specified dose on Specified days
ramucirumab
Specified dose on Specified days
lucitanib
Specified dose on Specified days
Local Institution, Ciudad Autónoma de Buenos Aires
Local Institution, Caba
Local Institution, Buenos Aires
Local Institution, Copenhagen Ø
Local Institution, Leuven
Local Institution, Charleroi
Local Institution, Gilly
Local Institution, Athens
Local Institution, Neo Faliro
Local Institution, Torreón
Local Institution, Zapopan
Local Institution, Detroit
Local Institution, Puebla City
Local Institution, Craiova
Local Institution, Timișoara
Local Institution, Buenos Aires
Local Institution, Capital
Local Institution, Mexico City
Local Institution, Amsterdam
Local Institution, Rotterdam
Local Institution, Oslo
Local Institution, Warsaw
Local Institution, Krakow
Lead Sponsor
Collaborators (2)
Clovis Oncology, Inc.
INDUSTRY
Exelixis
INDUSTRY
Eli Lilly and Company
INDUSTRY
Bristol-Myers Squibb
INDUSTRY